MedTrace Logo

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

NCT02117479 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 321

Last updated 2019-03-26

Study results available
· View outcomes & findings →

Summary

Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Ruxolitinib

5 mg tablets to be administered by mouth twice daily (BID)

DRUG

Placebo

5 mg tablets to be administered by mouth twice daily (BID)

DRUG

Capecitabine

150 and 500 mg tablets to be administered by mouth twice daily (BID)

Sponsors & Collaborators

Principal Investigators

  • Fitzroy Dawkins, M.D. · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-02-29
Completion
2016-12-31

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Germany
  • Italy
  • New Zealand
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02117479 on ClinicalTrials.gov